Cell Genesys Reports Encouraging Interim Data From Phase 1 Clinical Trial of CG0070 in Recurrent Bladder Cancer

Cell Genesys, Inc. (Nasdaq:CEGE) reported encouraging interim data from the expansion cohort of the Phase 1, multicenter clinical trial of CG0070 in patients with recurrent superficial bladder cancer who had failed therapy with Bacillus Calmette-Guerin (BCG), the current standard of care for this patient population. Sixteen patients have completed dosing of CG0070 administered once weekly or once every four weeks at the two lowest of three doses being evaluated. Ten of these sixteen patients showed anti-tumor activity as measured by complete response at follow-up cystoscopy. These data were presented by James M. McKiernan, M.D., vice chairman of urology and assistant professor of urology...

Want to see the full article?

• Purchase this article for only $3.00